COVID-19 UPDATE

BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For more
information on access to our products, please call our customer service line at 1-800-469-0261.

News Releases

News Releases

Date
Title
Document
December 20, 2017
BioDelivery Sciences Appoints Scott Plesha to President
PDF Version
December 18, 2017
BioDelivery Sciences Announces Notice of Allowance of Patent Strengthening Patent Protection on BELBUCA® to 2032
PDF Version
December 14, 2017
BioDelivery Sciences Reacquires ONSOLIS® from Collegium Pharmaceutical
PDF Version
November 16, 2017
BioDelivery Sciences to Present at the 29th Annual Piper Jaffray Conference
PDF Version
November 9, 2017
BioDelivery Sciences Reports Third Quarter 2017 Financial Results and Provides Corporate Update
PDF Version
October 30, 2017
BioDelivery Sciences to Host Conference Call and Webcast Reporting Third Quarter 2017 Financial Results on November 9
PDF Version
October 12, 2017
BioDelivery Sciences Announces Patent Litigation Settlement Agreement with Teva
PDF Version
October 6, 2017
BioDelivery Sciences Participates in U.S. Department of Health and Human Services Round Table Discussion on Pain Management and Opioid Dependence
PDF Version
September 19, 2017
BioDelivery Sciences to Present at the Cantor Fitzgerald Global Healthcare Conference and the Ladenburg Thalmann 2017 Healthcare Conference
PDF Version
September 12, 2017
BioDelivery Sciences Announces Granting of Market Authorization Transfer by Health Canada for BELBUCA® and Associated Milestone Payment Transfer of NDS to Purdue Pharma (Canada) triggers milestone payment to BDSI
PDF Version

Investor Presentation

More information is coming soon.


Upcoming Events

More events are coming soon.

Stay Connected

Stay up to date on the latest news

Get started now
March 24, 2021 /
Data provided by West LLC. Minimum 15 minutes delayed.